TY - JOUR
T1 - New scenarios in secondary hyperparathyroidism
T2 - etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of Nephrology
AU - Bellasi, Antonio
AU - Cozzolino, Mario
AU - Malberti, Fabio
AU - Cancarini, Giovanni
AU - Esposito, Ciro
AU - Guastoni, Carlo Maria
AU - Ondei, Patrizia
AU - Pontoriero, Giuseppe
AU - Teatini, Ugo
AU - Vezzoli, Giuseppe
AU - Pasquali, Marzia
AU - Messa, Piergiorgio
AU - Locatelli, Francesco
PY - 2020
Y1 - 2020
N2 - Bone mineral abnormalities (defined as Chronic Kidney Disease Mineral Bone Disorder; CKD-MBD) are prevalent and associated with a substantial risk burden and poor prognosis in CKD population. Several lines of evidence support the notion that a large proportion of patients receiving maintenance dialysis experience a suboptimal biochemical control of CKD-MBD. Although no study has ever demonstrated conclusively that CKD-MBD control is associated with improved survival, an expanding therapeutic armamentarium is available to correct bone mineral abnormalities. In this position paper of Lombardy Nephrologists, a summary of the state of art of CKD-MBD as well as a summary of the unmet clinical needs will be provided. Furthermore, this position paper will focus on the potential and drawbacks of a new injectable calcimimetic, etelcalcetide, a drug available in Italy since few months ago.
AB - Bone mineral abnormalities (defined as Chronic Kidney Disease Mineral Bone Disorder; CKD-MBD) are prevalent and associated with a substantial risk burden and poor prognosis in CKD population. Several lines of evidence support the notion that a large proportion of patients receiving maintenance dialysis experience a suboptimal biochemical control of CKD-MBD. Although no study has ever demonstrated conclusively that CKD-MBD control is associated with improved survival, an expanding therapeutic armamentarium is available to correct bone mineral abnormalities. In this position paper of Lombardy Nephrologists, a summary of the state of art of CKD-MBD as well as a summary of the unmet clinical needs will be provided. Furthermore, this position paper will focus on the potential and drawbacks of a new injectable calcimimetic, etelcalcetide, a drug available in Italy since few months ago.
KW - Cinacalcet
KW - CKD-MBD
KW - Etelcalcetide
KW - PTH
KW - Secondary hyperparathyroidism
UR - http://www.scopus.com/inward/record.url?scp=85077037538&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85077037538&partnerID=8YFLogxK
U2 - 10.1007/s40620-019-00677-0
DO - 10.1007/s40620-019-00677-0
M3 - Article
C2 - 31853791
AN - SCOPUS:85077037538
VL - 33
SP - 211
EP - 221
JO - Journal of Nephrology
JF - Journal of Nephrology
SN - 1121-8428
IS - 2
ER -